Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop

Brad S. Kahl*, Martin Dreyling, Leo I. Gordon, Leticia Quintanilla-Martinez, Eduardo M. Sotomayor

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1. Although MCL is associated with clinical heterogeneity, outcomes are generally poor and no standard treatment has been established. However, the recent approval of ibrutinib provides a new therapeutic option. Moreover, recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients. Multiple novel strategies are being evaluated in the treatment of MCL, including both targeted agents and cellular immunotherapies. At the Lymphoma Research Foundation’s 12th MCL Workshop, researchers gathered to discuss research findings, clinical trial results, and future directions related to MCL, its biology, and its treatment. This manuscript, which includes a summary of each presentation, aims to review recent findings in MCL research and highlight potential areas for future study.

Original languageEnglish (US)
Pages (from-to)1561-1569
Number of pages9
JournalLeukemia and Lymphoma
Volume58
Issue number7
DOIs
StatePublished - Jul 3 2017

Keywords

  • Lymphoma and Hodgkin’s disease
  • clinical results
  • immunotherapy
  • marrow and stem cell transplantation
  • pharmacotherapeutics
  • tumor microenvironment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop'. Together they form a unique fingerprint.

  • Cite this